Scribe Therapeutics Inc. Common Stock (SCTX) — Cash Flow-to-Debt Ratio
Scribe Therapeutics Inc. Common Stock (SCTX) has a Cash Flow-to-Debt Ratio of -0.02x as of June 2026, meaning its operating cash flow of $-5.34 Million could theoretically repay 0% of its total liabilities ($222.77 Million) in one year. See SCTX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Scribe Therapeutics Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Scribe Therapeutics Inc. Common Stock across 2 annual periods. See Scribe Therapeutics Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for Scribe Therapeutics Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Scribe Therapeutics Inc. Common Stock. For the full cash flow conversion analysis, see Scribe Therapeutics Inc. Common Stock cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.20x | $-45.21 Million | $221.64 Million | ▼ -14.5% |
| 2024 | -0.18x | $-45.23 Million | $253.83 Million | — |